Mesoblast Past Earnings Performance

Past criteria checks 0/6

Mesoblast has been growing earnings at an average annual rate of 0.5%, while the Biotechs industry saw earnings growing at 13.2% annually. Revenues have been declining at an average rate of 30.6% per year.

Key information

0.5%

Earnings growth rate

11.9%

EPS growth rate

Biotechs Industry Growth9.6%
Revenue growth rate-30.6%
Return on equity-18.3%
Net Margin-1,490.3%
Last Earnings Update30 Jun 2024

Recent past performance updates

Recent updates

Does Mesoblast (ASX:MSB) Have A Healthy Balance Sheet?

Jun 21
Does Mesoblast (ASX:MSB) Have A Healthy Balance Sheet?

Does Mesoblast (ASX:MSB) Have A Healthy Balance Sheet?

Jun 06
Does Mesoblast (ASX:MSB) Have A Healthy Balance Sheet?

Auditors Are Concerned About Mesoblast (ASX:MSB)

Sep 04
Auditors Are Concerned About Mesoblast (ASX:MSB)

Revenue & Expenses Breakdown

How Mesoblast makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

ASX:MSB Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 246-88240
31 Mar 247-82230
31 Dec 237-73240
30 Sep 238-81240
30 Jun 238-82250
31 Mar 238-81260
31 Dec 228-84270
30 Sep 228-86280
30 Jun 2210-91270
31 Mar 2210-92280
31 Dec 2110-97290
30 Sep 2110-97290
30 Jun 217-99310
31 Mar 216-109310
31 Dec 2016-98290
30 Sep 2016-9728-12
30 Jun 2032-78260
31 Mar 2033-6624-48
31 Dec 1922-7623-34
30 Sep 1922-7621-6
30 Jun 1917-90220
31 Mar 1916-902166
31 Dec 1816-862268
30 Sep 1828-482369
30 Jun 1817-35220
31 Mar 1816-422464
31 Dec 1716-302361
30 Sep 173-642360
30 Jun 172-772359
31 Mar 1729-12257
31 Dec 1632-82255
30 Sep 1635-112253
30 Jun 1643-42350
31 Mar 1620-832554
31 Dec 1520-882656
30 Sep 1520-942861
30 Jun 1520-963063
31 Mar 1521-852656
31 Dec 1424-842555
30 Sep 1426-752451
30 Jun 1423-762451
31 Mar 1430-682349
31 Dec 1335-582146

Quality Earnings: MSB is currently unprofitable.

Growing Profit Margin: MSB is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: MSB is unprofitable, but has reduced losses over the past 5 years at a rate of 0.5% per year.

Accelerating Growth: Unable to compare MSB's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: MSB is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (4.5%).


Return on Equity

High ROE: MSB has a negative Return on Equity (-18.31%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies